Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Maria Diaz"'
Autor:
Laura Evgin, Tim Kottke, Jason Tonne, Jill Thompson, Amanda L. Huff, Jacob van Vloten, Madelyn Moore, Josefine Michael, Christopher Driscoll, Jose Pulido, Eric Swanson, Richard Kennedy, Matt Coffey, Houra Loghmani, Luis Sanchez-Perez, Gloria Olivier, Kevin Harrington, Hardev Pandha, Alan Melcher, Rosa Maria Diaz, Richard G. Vile
Publikováno v:
Sci Transl Med
Oncolytic viruses (OVs) encoding a variety of transgenes have been evaluated as therapeutic tools to increase the efficacy of chimeric antigen receptor (CAR)–modified T cells in the solid tumor microenvironment (TME). Here, using systemically deliv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dae1ef8732f459386639d125fb6ef08f
https://europepmc.org/articles/PMC9297825/
https://europepmc.org/articles/PMC9297825/
Autor:
Cliona M. Rooney, Rosa Maria Diaz, Rehan Khan, Stephen J. Russell, Amber Miller, Yumei Zhou, Angela Dispenzieri, Deepak Upreti, Nandakumar Packiriswamy, Kah Whye Peng
Publikováno v:
Leukemia
Oncolytic virus therapy leads to immunogenic death of virus-infected tumor cells and this has been shown in preclinical models to enhance the cytotoxic T-lymphocyte response against tumor-associated antigens (TAAs), leading to killing of uninfected t
Publikováno v:
Biodrugs
New immuno-oncology therapies are improving cancer treatments beyond the former standard of care, as evidenced by the recent and continuing clinical approvals for immunotherapies in a broad range of indications. However, a majority of patients (parti
Autor:
Christy Ralph, Kevin J. Harrington, Jill Thompson, Shane Zaidi, Timothy Kottke, Richard G. Vile, Alan Melcher, Elizabeth Ilett, Matthew C. Coffey, Laura Evgin, Hardev Pandha, Rosa Maria Diaz, Richard J. Bram, Peter Selby, Karishma Rajani
Publikováno v:
Gene therapy
The anti-tumour effects associated with oncolytic virus therapy are mediated significantly through immune-mediated mechanisms, which depend both on the type of virus and the route of delivery. Here, we show that intra-tumoral oncolysis by Reovirus in
Autor:
Matthew C. Coffey, Richard G. Vile, Timothy Kottke, Hardev Pandha, Alan Melcher, Jill Thompson, Kevin J. Harrington, Shane Zaidi, Kevin G. Shim, Christopher Parrish, Liz Ilett, Rosa Maria Diaz, Karishma Rajani
Publikováno v:
Molecular Therapy. 24:166-174
Oncolytic reovirus can be delivered both systemically and intratumorally, in both preclinical models and in early phase clinical trials. Reovirus has direct oncolytic activity against a variety of tumor types and antitumor activity is directly associ
Autor:
Miran Blanchard, Kevin J. Harrington, Jill Thompson, Shane Zaidi, Richard G. Vile, Michael P. Grams, Rosa Maria Diaz, Kevin G. Shim, Kenneth R. Olivier, Keith M. Furutani, Hardev Pandha, Alan Melcher, Svetomir N. Markovic, Sean S. Park, Karishma Rajani
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 93:577-587
Purpose The oligometastatic state is an intermediate state between a malignancy that can be completely eradicated with conventional modalities and one in which a palliative approach is undertaken. Clinically, high rates of local tumor control are pos
Autor:
Alan Melcher, Richard G. Vile, Jill Thompson, Timothy Kottke, Rosa Maria Diaz, Timothy E. Peterson, Kevin G. Shim, Peter Selby, Karishma Rajani, Ian F. Parney, Elizabeth Ilett, Susan C Short, Shane Zaidi, Julia V. Cockle
Publikováno v:
Neuro-Oncology. 18:518-527
Background Systemic delivery of a complementary cDNA library expressed from the vesicular stomatitis virus (VSV) treats tumors by vaccinating against a wide range of tumor associated antigens (TAAs). For subcutaneous B16 melanomas, therapy was achiev
Autor:
Kevin G. Shim, Timothy Kottke, Nicolas Boisgerault, Kevin J. Harrington, Shane Zaidi, Jill Thompson, Laura Evgin, Peter Selby, Diana Rommelfanger, Hardev Pandha, Richard G. Vile, Rosa Maria Diaz, Elizabeth Ilett, Alan Melcher, Matthew C. Coffey
Understanding how incompletely cleared primary tumors transition from minimal residual disease (MRD) into treatment-resistant, immune-invisible recurrences has major clinical significance. We show here that this transition is mediated through the sub
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de43de651a3b9fba7a3b2ea55d6d0393
https://europepmc.org/articles/PMC5858196/
https://europepmc.org/articles/PMC5858196/
Autor:
Alan Melcher, Oliver Donnelly, Jill Thompson, Hardev Pandha, Candice Willmon, Matthew C. Coffey, Kevin J. Harrington, Shane Zaidi, Rosa Maria Diaz, Peter Selby, Timothy Kottke, Richard G. Vile, Elizabeth Ilett
Publikováno v:
Molecular Therapy. 22(10):1851-1863
Optimum clinical protocols require systemic delivery of oncolytic viruses in the presence of an intact immune system. We show that preconditioning with immune modulators, or loading virus onto carrier cells ex vivo, enhances virus-mediated antitumor
Autor:
Timothy Kottke, Rosa Maria Diaz, Jill Thompson, Diana Rommelfanger, Phonphimon Wongthida, Karen M. Kaluza, Richard G. Vile
Publikováno v:
Cancer Research. 72:4753-4764
Oncolytic virotherapy offers the potential to treat tumors both as a single agent and in combination with traditional modalities such as chemotherapy and radiotherapy. Here we describe an effective, fully systemic treatment regimen, which combines vi